Icure Pharmaceutical Incorporation아이큐어
175250 · KOSDAQ · ₩175250 · 아이큐어
₩1,371▼ ₩66 (4.59%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 8.1% | 5.3% | 11.0% | 2.3% | −9.4% | −7.2% |
| Operating margin | −2.4% | −14.3% | −24.8% | −39.9% | −45.1% | −44.0% |
| Net margin | −18.9% | −40.3% | 1.5% | −55.3% | −70.4% | −59.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +26.9% | +20.5% | +21.8% | −4.3% | −7.6% | — |
| Operating income growth | +79.1% | +30.4% | +24.2% | +15.4% | +5.3% | — |
| Net income growth | +40.4% | −3,302.3% | +103.3% | +24.8% | −9.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −73.5% | −77.6% | 1.8% | −42.5% | −45.0% | −39.9% |
| Return on assets | −22.7% | −30.9% | 0.0% | −16.6% | −19.4% | −17.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 251.7% | 270.0% | 118.8% | 178.8% | 144.0% | 118.3% |
| Net debt to equity | 61.7% | 69.6% | 38.9% | 117.4% | 39.4% | 56.8% |
| Current ratio | 61.2% | 58.8% | 85.3% | 33.3% | 73.4% | 107.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Icure Pharmaceutical Incorporation / 아이큐어 / 175250 / KRX:175250
Source: KRX statistical information